Tags

Type your tag names separated by a space and hit enter

Effect of a multispecies probiotic supplement on quantity of irritable bowel syndrome-related intestinal microbial phylotypes.
BMC Gastroenterol 2010; 10:110BG

Abstract

BACKGROUND

Probiotics can alleviate the symptoms of irritable bowel syndrome (IBS), possibly by stabilizing the intestinal microbiota. Our aim was to determine whether IBS-associated bacterial alterations were reduced during multispecies probiotic intervention consisting of Lactobacillus rhamnosus GG, L. rhamnosus Lc705, Propionibacterium freudenreichii ssp. shermanii JS and Bifidobacterium breve Bb99. The intervention has previously been shown to successfully alleviate gastrointestinal symptoms of IBS.

METHODS

The faecal microbiotas of 42 IBS subjects participating in a placebo-controlled double-blind multispecies probiotic intervention were analysed using quantitative real-time polymerase chain reaction (qPCR). Eight bacterial targets within the gastrointestinal microbiota with a putative IBS association were measured.

RESULTS

A phylotype with 94% similarity to Ruminococcus torques remained abundant in the placebo group, but was decreased in the probiotic group during the intervention (P = 0.02 at 6 months). In addition, the clostridial phylotype, Clostridium thermosuccinogenes 85%, was stably elevated during the intervention (P = 0.00 and P = 0.02 at 3 and 6 months, respectively). The bacterial alterations detected were in accordance with previously discovered alleviation of symptoms.

CONCLUSIONS

The probiotic supplement was thus shown to exert specific alterations in the IBS-associated microbiota towards the bacterial 16S rDNA phylotype quantities described previously for subjects free of IBS. These changes may have value as non-invasive biomarkers in probiotic intervention studies.

Authors+Show Affiliations

Department of Veterinary Biosciences, Faculty of Veterinary Medicine, University of Helsinki, Helsinki, Finland.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

20849659

Citation

Lyra, Anna, et al. "Effect of a Multispecies Probiotic Supplement On Quantity of Irritable Bowel Syndrome-related Intestinal Microbial Phylotypes." BMC Gastroenterology, vol. 10, 2010, p. 110.
Lyra A, Krogius-Kurikka L, Nikkilä J, et al. Effect of a multispecies probiotic supplement on quantity of irritable bowel syndrome-related intestinal microbial phylotypes. BMC Gastroenterol. 2010;10:110.
Lyra, A., Krogius-Kurikka, L., Nikkilä, J., Malinen, E., Kajander, K., Kurikka, K., ... Palva, A. (2010). Effect of a multispecies probiotic supplement on quantity of irritable bowel syndrome-related intestinal microbial phylotypes. BMC Gastroenterology, 10, p. 110. doi:10.1186/1471-230X-10-110.
Lyra A, et al. Effect of a Multispecies Probiotic Supplement On Quantity of Irritable Bowel Syndrome-related Intestinal Microbial Phylotypes. BMC Gastroenterol. 2010 Sep 19;10:110. PubMed PMID: 20849659.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effect of a multispecies probiotic supplement on quantity of irritable bowel syndrome-related intestinal microbial phylotypes. AU - Lyra,Anna, AU - Krogius-Kurikka,Lotta, AU - Nikkilä,Janne, AU - Malinen,Erja, AU - Kajander,Kajsa, AU - Kurikka,Kyösti, AU - Korpela,Riitta, AU - Palva,Airi, Y1 - 2010/09/19/ PY - 2010/01/10/received PY - 2010/09/19/accepted PY - 2010/9/21/entrez PY - 2010/9/21/pubmed PY - 2011/2/2/medline SP - 110 EP - 110 JF - BMC gastroenterology JO - BMC Gastroenterol VL - 10 N2 - BACKGROUND: Probiotics can alleviate the symptoms of irritable bowel syndrome (IBS), possibly by stabilizing the intestinal microbiota. Our aim was to determine whether IBS-associated bacterial alterations were reduced during multispecies probiotic intervention consisting of Lactobacillus rhamnosus GG, L. rhamnosus Lc705, Propionibacterium freudenreichii ssp. shermanii JS and Bifidobacterium breve Bb99. The intervention has previously been shown to successfully alleviate gastrointestinal symptoms of IBS. METHODS: The faecal microbiotas of 42 IBS subjects participating in a placebo-controlled double-blind multispecies probiotic intervention were analysed using quantitative real-time polymerase chain reaction (qPCR). Eight bacterial targets within the gastrointestinal microbiota with a putative IBS association were measured. RESULTS: A phylotype with 94% similarity to Ruminococcus torques remained abundant in the placebo group, but was decreased in the probiotic group during the intervention (P = 0.02 at 6 months). In addition, the clostridial phylotype, Clostridium thermosuccinogenes 85%, was stably elevated during the intervention (P = 0.00 and P = 0.02 at 3 and 6 months, respectively). The bacterial alterations detected were in accordance with previously discovered alleviation of symptoms. CONCLUSIONS: The probiotic supplement was thus shown to exert specific alterations in the IBS-associated microbiota towards the bacterial 16S rDNA phylotype quantities described previously for subjects free of IBS. These changes may have value as non-invasive biomarkers in probiotic intervention studies. SN - 1471-230X UR - https://www.unboundmedicine.com/medline/citation/20849659/Effect_of_a_multispecies_probiotic_supplement_on_quantity_of_irritable_bowel_syndrome_related_intestinal_microbial_phylotypes_ L2 - https://bmcgastroenterol.biomedcentral.com/articles/10.1186/1471-230X-10-110 DB - PRIME DP - Unbound Medicine ER -